



Male (n=9922)




Propensity score matching + adjust

Female (n=8056)




Male (n=9922)





Adjust

Female (n=18762)




Male (n=28998)







Predicted weight change (kg)

Predicted weight change (kg)







Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 11)
3–5 mmol/mol (n=491, event = 6)
0–3 mmol/mol (n=1975, event = 34)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2570, event = 57)
3–5 mmol/mol (n=1749, event = 42)
>5 mmol/mol (n=806, event = 31)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 27)
3–5 mmol/mol (n=1578, event = 31)
0–3 mmol/mol (n=3445, event = 113)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 82)
3–5 mmol/mol (n=330, event = 16)
>5 mmol/mol (n=170, event = 16)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Hazard Ratio

Hazard Ratio

Propensity score matching + adjusted

Hazard Ratio

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 11)
3-5 mmol/mol (n=491, event = 6)
0-3 mmol/mol (n=1975, event = 34)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2570, event = 57)
3-5 mmol/mol (n=1749, event = 42)
>5 mmol/mol (n=806, event = 31)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Hazard Ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 27)
3–5 mmol/mol (n=1578, event = 31)
0–3 mmol/mol (n=3445, event = 113)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 82)
3–5 mmol/mol (n=330, event = 16)
>5 mmol/mol (n=170, event = 16)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Adjusted

Female (n=22122)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1308, event = 22)
3-5 mmol/mol (n=1104, event = 9)
0-3 mmol/mol (n=4586, event = 64)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=7308, event = 148)
3-5 mmol/mol (n=5438, event = 105)
>5 mmol/mol (n=2378, event = 84)

Average treatment effect

0.50

1.0

2.0

Hazard Ratio

Male (n=29930)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=2928, event = 58) 3-5 mmol/mol (n=4223, event = 88)0-3 mmol/mol (n=11693, event = 318)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=9111, event = 264)3-5 mmol/mol (n=1325, event = 55)>5 mmol/mol (n=650, event = 45) Average treatment effect 0.35 0.50 0.71 1.0 1.41 2.0 Hazard Ratio

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 7)
3–5 mmol/mol (n=491, event = 3)
0–3 mmol/mol (n=1975, event = 11)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2570, event = 37)
3–5 mmol/mol (n=1749, event = 24)
>5 mmol/mol (n=806, event = 21)
Average treatment effect

0.088 0.125 0.177 0.250 0.354 0.500 0.707 1.00 1.410 2.00
Hazard Ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 12)
3–5 mmol/mol (n=1578, event = 17)
0–3 mmol/mol (n=3445, event = 68)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 44)
3–5 mmol/mol (n=330, event = 9)
>5 mmol/mol (n=170, event = 9)

Average treatment effect

0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0

Hazard Ratio

Propensity score matching + adjusted

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 7)
3–5 mmol/mol (n=491, event = 3)
0–3 mmol/mol (n=1975, event = 11)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2570, event = 37)
3–5 mmol/mol (n=1749, event = 24)
>5 mmol/mol (n=806, event = 21)

Average treatment effect

0.12 0.25 0.50 1.0 2.0

Hazard Ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 12)
3-5 mmol/mol (n=1578, event = 17)
0-3 mmol/mol (n=3445, event = 68)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2159, event = 44)
3-5 mmol/mol (n=330, event = 9)
>5 mmol/mol (n=170, event = 9)

Average treatment effect

0.062 0.125 0.250 0.500 1.001.410 2.00
Hazard Ratio

Adjusted

Female (n=22122)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1308, event = 12)
3–5 mmol/mol (n=1104, event = 7)
0–3 mmol/mol (n=4586, event = 28)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=7308, event = 86)
3–5 mmol/mol (n=5438, event = 63)
>5 mmol/mol (n=2378, event = 59)

Average treatment effect

0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83

Hazard Ratio

Male (n=29930)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2928, event = 30)
3-5 mmol/mol (n=4223, event = 36)
0-3 mmol/mol (n=11693, event = 157)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=9111, event = 122)
3-5 mmol/mol (n=1325, event = 31)
>5 mmol/mol (n=650, event = 24)

Average treatment effect

0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0


Hazard Ratio

Female (n=9095)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3-5 mmol/mol (n=522, event = 1)
0-3 mmol/mol (n=1982, event = 13)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2786, event = 24)
3-5 mmol/mol (n=1922, event = 16)

Male (n=9459)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)



Propensity score matching + adjusted

0.25

0.50

1.0

Hazard Ratio

2.0

4.0

Female (n=9095)

>5 mmol/mol (n=1225, event = 25)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3-5 mmol/mol (n=522, event = 1)
0-3 mmol/mol (n=1982, event = 13)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2786, event = 24)
3-5 mmol/mol (n=1922, event = 16)
>5 mmol/mol (n=1225, event = 25)

Average treatment effect


0.062 0.125 0.250 0.500 1.00 2.00 4.00

Hazard Ratio

Male (n=9459)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)
Average treatment effect



Adjusted

Female (n=23621)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1329, event = 11)
3-5 mmol/mol (n=1129, event = 2)
0-3 mmol/mol (n=4651, event = 27)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=7622, event = 71)
3-5 mmol/mol (n=5715, event = 46)
>5 mmol/mol (n=3175, event = 51)

Average treatment effect

0.50

1.0

2.0


4.0

8.0

Hazard Ratio

Male (n=31231)


Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2991, event = 32)
3–5 mmol/mol (n=4277, event = 39)
0–3 mmol/mol (n=11983, event = 146)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=9520, event = 127)
3–5 mmol/mol (n=1533, event = 33)
>5 mmol/mol (n=927, event = 20)
Average treatment effect



Female (n=10585)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=715, event = 3) 3–5 mmol/mol (n=578, event = 2) 0–3 mmol/mol (n=2265, event = 5) Predicted HbA1c benefit on GLP1–RA 0–3 mmol/mol (n=3249, event = 17) 3–5 mmol/mol (n=2267, event = 12) >5 mmol/mol (n=1511, event = 16) Average treatment effect 0.12 0.25 0.50 1.0 2.0

Male (n=12257)




Hazard Ratio


Propensity score matching + adjusted

Hazard Ratio

Female (n=10585)




Male (n=12257)



Adjusted

Female (n=27172)



Male (n=39256)

